ozempic and other glp-1 drugs Off-Label for Type 1 Diabetes The ABC's of GLP-1s: Benefits,
Description
Agarwal SM, Stogios N, Ahsan ZA, Lockwood JT, Duncan MJ, Takeuchi H, et al
doi: 10.1111/dom.15620
The trial also reported dose-dependent increases in heart rate that peaked at 24 weeks and declined thereafter
Products that do not disclose testing practices or provide clear contact information should be approached with caution, particularly when marketed for metabolic or weight-related outcomes
Repurposed by Pleiogenix with 4 NIH grants, led to a first-in-class, non-steroid drug for Alcoholic Hepatitis, a $3.B+ mkt without any approved FDA drugs
